Kronos Bio(US:KRON) globenewswire.comยท2024-05-23 21:15Core Insights - Kronos Bio, Inc. presented new data on KB-0742, a small molecule therapeutic targeting CDK9, at the 2024 ASCO Annual Meeting, indicating a manageable safety profile and promising efficacy in treating relapsed or refractory solid tumors and non-Hodgkin lymphoma [1][2][4] Company Overview - Kronos Bio, Inc. is focused on developing small molecule therapeutics that target deregulated transcription, a key factor in cancer and other diseases [7] - The company has a proprietary discovery engine that identifies druggable cofactors within complex transcription factor regulatory networks [7] Drug Development - KB-0742 is currently in a Phase 1/2 study (KB-0742-1001) and has shown a deepening reduction of CDK9-sensitive transcripts at the 80mg dose compared to the 60mg dose [2][9] - The ongoing study includes 103 patients with transcription factor fusion or MYC-driven tumors, with a median of three prior treatments [6] - The 80mg four-days-on, three-days-off dosing schedule is expected to enhance efficacy, with enrollment for the expansion cohort anticipated to begin in Q3 2024 [3][5] Efficacy and Safety Data - Preliminary data from the study indicated manageable mild to moderate adverse events, with no grade 3/4 neutropenia observed [6] - Patients treated with KB-0742 exhibited anti-tumor activity, including stable disease responses of 71 days for a non-small-cell lung cancer patient and over 195 days for a platinum-resistant ovarian cancer patient [6] Future Expectations - The company is optimistic about the potential increased patient benefit from the 80mg dosing schedule, supported by pharmacokinetic modeling showing a greater than ten-fold increase in time above a preclinically determined efficacy threshold compared to the 60mg schedule [5][6]